Ameriprise Financial Inc Aptinyx Inc. Transaction History

Ameriprise Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.38 - $2.58 $380 - $2,580	-1,000 Reduced 7.04%	13,200 $7,000
Q1 2022 May 16, 2022	SELL	$2.27 - $3.62 $6,810 - $10,860	-3,000 Reduced 17.44%	14,200 $32,000
Q3 2021 Nov 15, 2021	SELL	$2.21 - $2.89 $4,420 - $5,780	-2,000 Reduced 10.42%	17,200 $40,000
Q2 2021 Aug 16, 2021	BUY	$2.39 - $3.5 $9,321 - $13,650	3,900 Added 25.49%	19,200 $54,000
Q1 2021 May 17, 2021	BUY	$2.86 - $4.33 $43,758 - $66,249	15,300 New	15,300 $46,000
Q4 2020 Feb 12, 2021	SELL	$2.93 - $4.3 $40,056 - $58,785	-13,671 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.05 - $4.99 $6,100 - $9,980	2,000 Added 17.14%	13,671 $46,000
Q2 2020 Aug 14, 2020	BUY	$1.99 - $4.4 $23,225 - $51,352	11,671 New	11,671 $49,000
Q1 2020 May 15, 2020	SELL	$1.81 - $5.03 $35,088 - $97,511	-19,386 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$2.84 - $4.25 $14 - $21	-5 Reduced 0.03%	19,386 $66,000
Q3 2019 Nov 14, 2019	BUY	$3.0 - $4.08 $58,173 - $79,115	19,391 New	19,391 $68,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.